ERNA · Ernexa Therapeutics Inc.
$4.74
-0.16 (-3.17%)
At close · Aug 27
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“we evaluated whether there are conditions and events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of August 4, 2026, we had approximately $7.4 million in cash, which is less than that needed to affect our current operating plan and forecasted cash requirements for the next twelve months. However, we expect that our ability to access additional capital under our ATM will cover shortfalls in our cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$7.73M
Shares
1.63M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-04-11 | New | Biotechnology | $7,249,999 | $7,249,999 | 06b |
| 2024-11-14 | New | Biotechnology | $3,887,252 | $3,887,252 | 06b |
| 2024-11-14 | New | Biotechnology | $1,137,746 | $1,137,746 | 06b |
| 2023-12-20 | New | Biotechnology | $9,193,000 | $7,788,000 | 06b |
| 2023-07-26 | New | Biotechnology | $8,715,000 | $8,715,000 | 06b |
| 2023-07-26 | New | Biotechnology | $8,715,000 | $8,715,000 | 06b |
| 2022-12-16 | New | Biotechnology | $7,712,874 | $7,712,874 | 06b |
| 2022-03-23 | New | Biotechnology | $12,000,000 | $12,000,000 | 06b |
Showing 1–8 of 8 filings
Key facts
CIK
748592
CUSIP
114082407
13F (30d)
14 filings
14 filers
Visit website
Investor relations